US proposal on drug pricing may shake up Indian pharma
The move to outlaw rebates poses an existential challenge to Indian drugmakers
In response to President Trump’s complaints over escalating healthcare costs in the US, Pfizer announced it will defer its previously-planned price increases for later this year. What appears to be a generous concession, however, is a warning sign that the prices for Pfizer’s branded products are about to increase sharply.